STSA · Satsuma Pharmaceuticals Inc

-

Please sign in to comment on STSA

1 Comment

Admin

4 years ago

Satsuma Pharmaceuticals, Inc is currently in a long term uptrend where the price is trading 28.8% above its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Satsuma Pharmaceuticals, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has increased by 99.6% to $-48K since the same quarter in the previous year.

Finally, its free cash flow fell by 79.0% to $-13M since the same quarter in the previous year.

Based on the above factors, Satsuma Pharmaceuticals, Inc gets an overall score of 3/5.

Exchange	NASDAQ
CurrencyCode	USD
Sector	Healthcare
Industry	Biotechnology
ISIN	US80405P1075

Beta	0.1
Market Cap	37M
PE Ratio	None
Target Price	2
Dividend Yield	0.0%

ABOUT

Satsuma Pharmaceuticals Inc

Satsuma Pharmaceuticals, Inc., a development-stage biopharmaceutical company, develops novel therapeutic products for the acute treatment of migraines. The company's product candidature includes STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. As of June 8, 2023, Satsuma Pharmaceuticals, Inc. operates as a subsidiary of Shin Nippon Biomedical Laboratories, Ltd.

STSA · Satsuma Pharmaceuticals Inc

-

Satsuma Pharmaceuticals Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Satsuma Pharmaceuticals Inc using a moving average strategy